IRCT20200422047168N1已完成2 期
Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •1- People over 18 years of age,
- •2- Real-time PCR positive test result for SARS-CoV-2 virus was positive after sampling (nasopharynx and oropharynx swab samples).
- •3. The manifestations of pneumonia caused by the virus in CT scans of their lungs are quite obvious.
- •4- They have 93% or lower O2 Saturation percentage
排除标准
- •1- History of renal failure,
- •2- Taking drugs that interfere with Tenofovir
- •3. Patients who have been admitted to other clinical trials
研究者
相似试验
已完成
不适用
Comparisons of efficacy and safety between Tenofovir and Entecavir drugs in chronic hepatitis B patientsInfections and InfestationsHepatitis BISRCTN18291875Kaohsiung Chang Gung Memorial Hospital288
招募中
3 期
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours vs 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir induced renal dysfunction.chronic hepatitis Brenal impairmentHBV viral controltenofovirdose reductionrenal impairmentTCTR20180207001Gastroenterological Association of Thailand108
已完成
3 期
Comparative study between Entecavir and Tenofovir in the treatment of chronic hepatitis B infection in Thai patientsChronic hepatitis B infectionChronic hepatitis B,Tenofovir,Entecavir,Efficacy,SafetyTCTR20180626002Chulabhorn Hospital442
已完成
4 期
Effectiveness and Safety of Tenofovir + Lamivudine + Efavirenz Generic Scheme for the Treatment of HIV Infection / AIDS in Patients of the CLS,Colombia, 2012-2013.HIV/AIDSRPCEC00000134Corporación de Lucha Contra el Sida80
进行中（未招募）
Unknown
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsEffectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B patientsInfections and InfestationsISRCTN80908109GlaxoSmithKline (China) Investment Co., Ltd.2,000